The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD

C. Fogarty, E. Kerwin, K. Dunn, D. Singh, A. Tutuncu (Spartanburg, Medford, Raleigh, San Diego, United States Of America; Manchester, United Kingdom)

Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Session: Translational respiratory medicine in asthma and COPD
Session type: Thematic Poster Session
Number: 2194
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
C. Fogarty, E. Kerwin, K. Dunn, D. Singh, A. Tutuncu (Spartanburg, Medford, Raleigh, San Diego, United States Of America; Manchester, United Kingdom). The GOLDEN-1 study: Safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD. Eur Respir J 2012; 40: Suppl. 56, 2194

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Efficacy and safety of nebulized glycopyrrolate (EP-101) for administration using high efficiency nebulizer in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

Efficacy of nebulized arformoterol, a long-acting β2-adrenergic bronchodilator, in patients with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 215s
Year: 2006

A comparison of nebulized levalbuterol, albuterol, and combined albuterol and ipratropium in patients with stable COPD: preliminary observations
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD
Source: Annual Congress 2010 - Combination therapy in asthma and COPD
Year: 2010

Efficacy and safety of AZD3199, an inhaled ultra long-acting β2-agonist, in patients with COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011

RPL554, an inhaled PDE3/4 inhibitor, causes comparable bronchodilation to high dose nebulised salbutamol in asthmatics with fewer systemic effects
Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma
Year: 2016

A comparison of tiotropium inhalation capsules and ipratropium metered dose inhaler in a double-blind, efficacy and safety study in Chinese adults with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2006; 28: Suppl. 50, 213s
Year: 2006

Cardiovascular effects of a high dose of the budesonide/formoterol single inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 54s
Year: 2001

Does the inhalation device affect the bronchodilatory dose response curve of Salbutamol in asthma- and COPD patients?
Source: Eur Respir J 2003; 22: Suppl. 45, 473s
Year: 2003

Cardiovascular safety of extrafine beclomethasone/formoterol (BDP/FF) delivered via a novel dry powder inhaler (NEXThaler®) in COPD patients
Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD
Year: 2015


Dose-finding study for tiotropium and olodaterol when administered in combination via the Respimat® inhaler in patients with COPD
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012


Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients
Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD
Year: 2020




Population pharmacokinetics of nebulized arformoterol in subjects with COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 427s
Year: 2006

Efficacy of tiotropium bromide inhalation combined with or without low dose theophylline for moderate to severe stable Chinese COPD patients
Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics
Year: 2013

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Effects of acute dual bronchodilator treatment (tiotropium + olodaterol) on cardiopulmonary interactions in hyperinflated patients with COPD
Source: International Congress 2018 – Advances in exercise physiopathology
Year: 2018



Long acting bronchodilation of Spiriva® handihaler in COPD patients, the influence of the inhalation flow rate (IFR)
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008


Comparison of the pharmacokinetics and pharmacodynamics of once daily tiotropium Respimat® and tiotropium HandiHaler® in COPD patients
Source: Annual Congress 2013 –LAMA, LABA, ICS and their combinations for the treatment of asthma and COPD
Year: 2013



Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS)
Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD
Year: 2015

NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD
Source: Eur Respir J 2006; 28: Suppl. 50, 527s
Year: 2006